arrow
N

Nobuhisa Ishikawa

Hiroshima Prefectural Hospital
H指数:43
被引数:6,929

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI-Platinum Therapy (WJOG14120L)

WJOG14120L研究:接受ICI-铂类方案治疗后鳞状非小细胞肺癌患者接受顺铂/吉西他滨联合尼昔妥木单抗治疗的II期研究

2026-10-010
OAAI
Predictive value of Eastern Cooperative Oncology Group performance status and body mass index for antifibrotic tolerability and prognosis in patients with idiopathic pulmonary fibrosis

东欧合作肿瘤学研究组体能状态和体重指数对特发性肺纤维化患者抗纤维化治疗耐受性及预后的预测价值

2025-11-010
OA
Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study

日本肺癌患者中静脉血栓栓塞症的发病率和临床特征:CS-Lung-003前瞻性观察性登记研究的结果

2025-11-010
OAAI
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

度鲁妥单抗、卡铂和依托泊苷用于治疗初治广泛期小细胞肺癌且体力状况较差的患者(NEJ045A):一项单臂Ⅱ期试验

2025-09-280
PRE
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab与erlotinib联合作为携带<i>EGFR</i>外显子21 L858R突变的晚期或复发非小细胞肺癌的一线治疗:一项在日本进行的多中心回顾性观察队列研究(REAL-SPEED)。

2025-06-160
OA
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响:NINJA研究的亚组分析

2025-02-140
OA
Effect of telomere length and TERT/TERC rare variants on survival in Japanese patients with idiopathic interstitial pneumonias :Genetic predisposition study from the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry (NEJ036A)
2024-10-300
PRE
Nationwide All ILD registry with central MDD in Japan; Providing Multidisciplinary ILD diagnoses (PROMISE) study.
2023-10-271
PRE
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
2022-12-183
OAAI
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
2022-07-291
OAAI
Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study)

晚期肺癌患者静脉血栓栓塞发生率及直接口服抗凝剂的疗效和安全性: 一项多中心、前瞻性、观察性研究 (Rising-VTE/NEJ037研究)

2022-07-2111
OAAI
A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study
2022-04-0415
OAAI
Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
2022-02-1414
OAAI
Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
2021-05-2119
OAAI
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
2021-02-272
OAAI
Diagnosis and treatment of new idiopathic interstitial pneumonias cases: Analysis using the Japanese Registry
2020-10-280
PRE